Show simple item record

dc.contributor.authorÁlvaro Meca, Luis Alejandro
dc.contributor.authorJiménez-Sousa, María A.
dc.contributor.authorBoyer, Alexandre
dc.contributor.authorMedrano Laporte, José ORCID
dc.contributor.authorReulen, Holger
dc.contributor.authorKneib, Thomas
dc.contributor.authorResino, Salvador
dc.date.accessioned2018-02-05T14:25:46Z
dc.date.available2018-02-05T14:25:46Z
dc.date.issued2016-03-12
dc.identifier.citationBMC Infectious Diseases 16 : (2016) // Article ID 122es_ES
dc.identifier.issn1471-2334
dc.identifier.urihttp://hdl.handle.net/10810/24829
dc.description.abstractBackground: Cirrhosis and severe sepsis are factors associated with increased mortality in intensive care unit (ICU), but chronic hepatitis C (CHC) has been less studied in ICU. The aim of this study was to analyze the impact of CHC on the mortality of cirrhotic patients admitted to ICU according to severe sepsis and decompensated cirrhosis. Methods: We carried out a retrospective study based on CHC-cirrhotic patients (CHC-group) admitted to ICU (n = 1138) and recorded in the Spanish Minimum Basic Data Set (2005-2010). A control-group (randomly selected cirrhotic patients without HIV, HBV, or HCV infections) was also included (n = 4127). The primary outcome variable was ICU mortality. The cumulative mortality rate on days 7, 30, and 90 in patients admitted to the ICUs was calculated by dividing the number of deaths by the number of patients admitted to the ICU. The adjusted hazard ratio (aHR) for death in the ICU was estimated through a semi-parametric Bayesian model of competing risk. Results: The CHC-group had a higher cumulative incidence of severe sepsis than the control-group in compensated cirrhosis (37.4 vs. 31.1 %; p = 0.024), but no differences between the CHC-group and the control-group in decompensated cirrhosis were found. Moreover, a higher cumulative incidence of severe sepsis was associated with decompensated cirrhosis compared to compensated cirrhosis in the control-group (40.1 vs. 31.1 %; p < 0.001) whereas this was not observed in the CHC group (38.1 vs. 37.4 %; p = 0.872). The CHC-group had higher cumulative mortality than the control-group by days 7 (47 vs. 41.3 %; p < 0.001), 30 (78.5 vs. 73.5 %; p < 0.001), and 90 (96.3 vs. 95.9 %; p < 0.001). In a competitive risk model, the CHC-group had a higher risk of dying if the ICU course was complicated by severe sepsis (adjusted hazard ratio (aHR) = 1.19; p = 0.003), but no significant values in patients with absence of severe sepsis were found (aHR = 1.09; p = 0.068). When patients were stratified by cirrhosis stage and severe sepsis, CHC patients with compensated cirrhosis had the higher risk of death if they had severe sepsis (aHR = 1.35; p = 0.002). Moreover, the survival was low in patients with decompensated cirrhosis and severe sepsis but we did not find significant differences between CHC-group and control-group. Conclusions: CHC was associated with an increased risk of death in cirrhotic patients admitted to ICUs, particularly in patients with compensated cirrhosis and severe sepsis.es_ES
dc.description.sponsorshipThis research has been supported by Instituto de Salud Carlos III (grant numbers PI11/00245 & PI14CIII/00011 to SR and PI12/00019 to AAM). MAJS is supported by a contract of "Instituto de Salud Carlos III" (grant number CD13/00013).es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectcritical carees_ES
dc.subjectsurvivales_ES
dc.subjectchronic hepatitis Ces_ES
dc.subjectsevere sepsises_ES
dc.subjectHCVes_ES
dc.subjectchronic liver-failurees_ES
dc.subjectbacterial-infectionses_ES
dc.subjectIimmune paralysises_ES
dc.subjectscoring systemses_ES
dc.subjectorgan failurees_ES
dc.subjectseptic shockes_ES
dc.subjectprognosises_ES
dc.subjectepidemiologyes_ES
dc.titleImpact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unites_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2016 Álvaro-Meca et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise statedes_ES
dc.rights.holderAtribución 3.0 España
dc.relation.publisherversionhttps://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-016-1448-8?site=bmcinfectdis.biomedcentral.comes_ES
dc.identifier.doi10.1186/s12879-016-1448-8
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2016 Álvaro-Meca et al.
Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated
Except where otherwise noted, this item's license is described as © 2016 Álvaro-Meca et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated